MARKET

DTIL

DTIL

Precision Biosciences
NASDAQ
3.960
-0.110
-2.70%
Closed 19:54 02/12 EST
OPEN
4.060
PREV CLOSE
4.070
HIGH
4.085
LOW
3.750
VOLUME
224.36K
TURNOVER
0
52 WEEK HIGH
8.82
52 WEEK LOW
3.530
MARKET CAP
95.32M
P/E (TTM)
-0.4714
1D
5D
1M
3M
1Y
5Y
1D
BUZZ-U.S. STOCKS ON THE MOVE-Micron, McDonald's, Generac
Reuters · 1d ago
BUZZ-U.S. STOCKS ON THE MOVE-Klaviyo, Frontier Group, Wabtec
Reuters · 1d ago
BUZZ-U.S. STOCKS ON THE MOVE-Shopify, GlobalFoundries, Constellation Energy
Reuters · 1d ago
BUZZ-Precision BioSciences jumps after FDA clears trial for muscle‑wasting disease therapy
Reuters · 1d ago
Precision BioSciences Receives Study May Proceed Notification From FDA, Allowing Co To Initiate IRB Activities And Clinical Trial Site Activation For FUNCTION-DMD Phase 1/2 Clinical Trial For PBGENE-DMD
Benzinga · 1d ago
FDA Clears Precision BioSciences to Begin Clinical Trial for Duchenne Muscular Dystrophy Therapy
Reuters · 1d ago
PRECISION BIOSCIENCES RECEIVES U.S. FDA CLEARANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR FIRST-IN-CLASS PBGENE-DMD FOR TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
Reuters · 1d ago
Weekly Report: what happened at DTIL last week (0202-0206)?
Weekly Report · 4d ago
More
About DTIL
Precision BioSciences, Inc. is a clinical-stage gene editing company dedicated to improving life (DTIL) with its proprietary ARCUS genome editing platform. Using ARCUS, the Company’s pipeline is comprised of in vivo gene editing candidates designed to deliver cures for a range of genetic and infectious diseases. The ARCUS platform is used to develop in vivo gene editing therapies for gene edits, including gene insertion, elimination, and excision. The Company's in vivo gene editing pipeline programs include PBGENE-HBV, PBGENE-3243, PBGENE-DMD, PBGENE-LIVER, PBGENE-CNS, PBGENE-NVS and iECURE-OTC. PBGENE-HBV is its lead in vivo gene editing program designed to eliminate cccDNA, the key source of replicating hepatitis B virus (HBV) and inactivating integrated HBV DNA in hepatocytes. Its PBGENE-3243 program is a first of its kind potential treatment for m.3243 associated mitochondrial disease. The Company's iECURE-OTC program is developed in partnership with iECURE, Inc.

Webull offers Precision BioSciences Inc stock information, including NASDAQ: DTIL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DTIL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DTIL stock methods without spending real money on the virtual paper trading platform.